Physician profile
Michael J Trimble
NPI 1770859639
$844.67
in general payments reported to CMS, 2019-2025
14 companies · $692 in 2025
The $692 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.34 · 2023: $32.94 · 2024: $79.73 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $136.78 | 2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $125.93 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $121.34 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $86.22 | 2025 | Korlym |
| Abbvie INC. | $72.02 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.09 | 2025 | Caplyta |
| Abbott Laboratories | $49.09 | 2022-2024 | Freestyle Libre 2 |
| Amgen INC. | $45.88 | 2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $43.74 | 2025 | Shingrix |
| Astellas Pharma US INC | $25.20 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $21.94 | 2025 | |
| Axsome Therapeutics, INC. | $20.90 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $16.64 | 2025 | Lagevrio |
| Exact Sciences Corporation | $13.90 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Trimble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.